Phaseline

Companies › Anbogen Therapeutics

Anbogen Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ABT-101
HER2 tyrosine kinase inhibitor
ERBB2Phase 1Advanced Solid TumorNov 2026
ABT-301
Histone deacetylase inhibitor (HDACi)
–Phase 1Colorectal Cancer (Diagnosis)Apr 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05532696ABT-101Phase 1Advanced Solid TumorOncologyNov 2026
NCT07244705ABT-301Phase 1Colorectal Cancer (Diagnosis)OncologyApr 2028

Targets

ERBB2 (1)

Companies with the same targets

Beijing Biotech Roche Jiangsu HengRui Medicine Shenyang Sunshine Pharmaceutical Suzhou Suncadia Biopharmaceuticals Pfizer Sichuan Baili Pharmaceutical Shanghai Henlius Biotech Chia Tai Tianqing Pharmaceutical Group Yuhan

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.